Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study.
Altomare D, Collij L, Caprioglio C, Scheltens P, van Berckel BNM, Alves IL, Berkhof J, de Gier Y, Garibotto V, Moro C, Poitrine L, Delrieu J, Payoux P, Saint-Aubert L, Molinuevo JL, Grau-Rivera O, Gispert JD, Minguillón C, Fauria K, Sanchez MF, Rădoi A, Drzezga A, Jessen F, Escher C, Zeyen P, Nordberg A, Savitcheva I, Jelic V, Walker Z, Lee HY, Lee L, Demonet JF, Plaza Wuthrich S, Gismondi R, Farrar G, Barkhof F, Stephens AW, Frisoni GB; AMYPAD Consortium. Altomare D, et al. Among authors: walker z. Alzheimers Dement. 2022 Jun 17. doi: 10.1002/alz.12696. Online ahead of print. Alzheimers Dement. 2022. PMID: 35715930
Long-term outcome of depressive pseudodementia in the elderly.
Sáez-Fonseca JA, Lee L, Walker Z. Sáez-Fonseca JA, et al. Among authors: walker z. J Affect Disord. 2007 Aug;101(1-3):123-9. doi: 10.1016/j.jad.2006.11.004. Epub 2006 Dec 20. J Affect Disord. 2007. PMID: 17184844
Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease.
Salloway S, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Escovar YM, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Farrar G, Smith APL, Buckley CJ, Thal DR, Zanette M, Curtis C. Salloway S, et al. Among authors: walker z. Alzheimers Dement (Amst). 2017 Jul 1;9:25-34. doi: 10.1016/j.dadm.2017.06.001. eCollection 2017. Alzheimers Dement (Amst). 2017. PMID: 28795133 Free PMC article.
Clinical utility of FDG-PET for the clinical diagnosis in MCI.
Arbizu J, Festari C, Altomare D, Walker Z, Bouwman F, Rivolta J, Orini S, Barthel H, Agosta F, Drzezga A, Nestor P, Boccardi M, Frisoni GB, Nobili F; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Arbizu J, et al. Among authors: walker z. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1497-1508. doi: 10.1007/s00259-018-4039-7. Epub 2018 Apr 27. Eur J Nucl Med Mol Imaging. 2018. PMID: 29704037 Review.
Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease.
Agosta F, Altomare D, Festari C, Orini S, Gandolfo F, Boccardi M, Arbizu J, Bouwman F, Drzezga A, Nestor P, Nobili F, Walker Z, Pagani M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Agosta F, et al. Among authors: walker z. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1546-1556. doi: 10.1007/s00259-018-4033-0. Epub 2018 May 1. Eur J Nucl Med Mol Imaging. 2018. PMID: 29717332 Review.
Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders.
Nobili F, Festari C, Altomare D, Agosta F, Orini S, Van Laere K, Arbizu J, Bouwman F, Drzezga A, Nestor P, Walker Z, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Nobili F, et al. Among authors: walker z. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1557-1566. doi: 10.1007/s00259-018-4030-3. Epub 2018 May 2. Eur J Nucl Med Mol Imaging. 2018. PMID: 29721650 Review.
Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.
Nestor PJ, Altomare D, Festari C, Drzezga A, Rivolta J, Walker Z, Bouwman F, Orini S, Law I, Agosta F, Arbizu J, Boccardi M, Nobili F, Frisoni GB; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Nestor PJ, et al. Among authors: walker z. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1509-1525. doi: 10.1007/s00259-018-4035-y. Epub 2018 May 7. Eur J Nucl Med Mol Imaging. 2018. PMID: 29736698 Review.
Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia.
Bouwman F, Orini S, Gandolfo F, Altomare D, Festari C, Agosta F, Arbizu J, Drzezga A, Nestor P, Nobili F, Walker Z, Morbelli S, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Bouwman F, et al. Among authors: walker z. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1526-1533. doi: 10.1007/s00259-018-4034-z. Epub 2018 May 9. Eur J Nucl Med Mol Imaging. 2018. PMID: 29744573 Free PMC article.
Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease.
Drzezga A, Altomare D, Festari C, Arbizu J, Orini S, Herholz K, Nestor P, Agosta F, Bouwman F, Nobili F, Walker Z, Frisoni GB, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Drzezga A, et al. Among authors: walker z. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1487-1496. doi: 10.1007/s00259-018-4032-1. Epub 2018 May 13. Eur J Nucl Med Mol Imaging. 2018. PMID: 29756163 Review.
216 results